Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy

Histone deacetylase inhibitors (HDACi) are currently being explored for the treatment of both solid and hematological malignancies. Although originally thought to exert cytotoxic responses through tumor-intrinsic mechanisms by increasing expression of tumor suppressor genes, several studies have dem...

Descripción completa

Detalles Bibliográficos
Autores principales: Holay, Nisha, Somma, Alexander, Duchow, Mark, Soleimani, Milad, Capasso, Anna, Kottapalli, Srividya, Rios, Joshua, Giri, Uma, Diamond, Jennifer, Schreiber, Anna, Piscopio, Anthony D., Van Den Berg, Carla, Eckhardt, S. Gail, Triplett, Todd A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10513502/
https://www.ncbi.nlm.nih.gov/pubmed/37744352
http://dx.doi.org/10.3389/fimmu.2023.1260545

Ejemplares similares

Ejemplares similares